Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05147051
Other study ID # RB-II-2020
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 16, 2021
Est. completion date June 22, 2022

Study information

Verified date October 2022
Source POLYSAN Scientific & Technological Pharmaceutical Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An acid-base imbalance, called metabolic acidosis (acid-base disorder lasting from several minutes to several days, caused by a decrease in serum bicarbonate ion (HCO3) concentration), is often observed in critically ill patients with various underlying diseases. Metabolic acidosis has a negative impact on the cardiovascular, respiratory, digestive, nervous, excretory, hematological, endocrine, musculoskeletal and immune systems and is associated with unfavourable outcomes. Reamberin® is a solution of disubstituted sodium salt of succinic acid, which has an alkaline reaction and succinate is capable to integrate into the Krebs cycle and restore energy metabolism in the cell. The aim of the present study is to evaluate the efficacy and safety of meglumine sodium succinate at a dose of 500 to 3000 ml in critically ill patients with metabolic acidosis and choose the optimal volume of its solution for the correction of metabolic acidosis in critically ill patients.


Recruitment information / eligibility

Status Completed
Enrollment 140
Est. completion date June 22, 2022
Est. primary completion date May 23, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Signed and dated written Informed Consent (if unconscious due to a critical condition, the decision is made by a Council consisting of 3 physicians) 2. Male and female patients aged 18-70 3. Critical illness ((shock (including traumatic, hypovolemic), major trauma, acute massive blood loss, acute complicated surgical diseases of the abdominal organs) accompanied by metabolic acidosis, defined as serum bicarbonate <22mmol/L 4. pH of arterial blood 7.20-7.35, inclusive 5. Planned volume of infusion >= 1500 ml per day 6. Interval between admission to the ICU and randomization <24 hours Exclusion Criteria: 1. Pregnant and lactating women 2. Known hypersensitivity to any component of the study drug / placebo 3. Chronic kidney disease stage C5 (end-stage renal failure) 4. Acute hepatic failure (ALT > 15 upper normal limits) or liver cirrhosis 5. Traumatic brain injury accompanied by cerebral edema 6. Previously diagnosed mental illness 7. Any chronic disease in the terminal stage with a life expectancy of < 3 months 8. HIV infection 9. Clinically significant cardiovascular disease (unstable angina pectoris or angina pectoris of functional class III or higher; chronic heart failure III - IV class according to NYHA; acute myocardial infarction within 6 months before screening) 10. Extremely low or extremely high body fat 11. Infusion sodium bicarbonate, sodium bicarbonate, trometamol, Sterofundin, Quintasol, Ringer's lactate (Hartmann's solution) within 6 hours before screening 12. Acute respiratory acidosis 13. Poisoning with chemical compounds causing metabolic acidosis 14. Alcohol in saliva at screening >= 0.5 pro mille 15. Previously diagnosed chronic obstructive pulmonary disease

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Meglumine Sodium Succinate
500 ml of 1.4% solution IV at a rate of at least 4 ml and not more than 10 ml per minute
Placebo
Ringer's solution, 500 ml IV at a rate of at least 4 ml and not more than 10 ml per minute

Locations

Country Name City State
Russian Federation GBUZ Arkhangelsk region "First GKB named after E.E. Volosevich" Arkhangel'sk
Russian Federation Ivanovo Regional Clinical Hospital Ivanovo
Russian Federation Central Clinical Hospital with a polyclinic of the Office of the President of the Russian Federation Moscow
Russian Federation Privolzhsky District Medical Center Nizhny Novgorod
Russian Federation Saint-Petersburg I.I.Dzanelidze Research Institute of Emergency Medicine Saint Petersburg
Russian Federation National Research Mordovian State University n.a. N.P. Ogarev Saransk

Sponsors (2)

Lead Sponsor Collaborator
POLYSAN Scientific & Technological Pharmaceutical Company Atlant Clinical Ltd.

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Elimination of acidosis at 24 hours after the start of treatment The proportion of patients who have achieved normalization of the serum bicarbonate level (normalization = serum hydrocarbonate ion concentration =22 mmol / Liter), at 24 hours after the start of therapy. 24 hours
See also
  Status Clinical Trial Phase
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Completed NCT03317444 - Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease Phase 3
Recruiting NCT05582824 - Lactate Metabolism in the Hypoperfused Critically Ill
Active, not recruiting NCT04010630 - Sodium Bicarbonate for the Treatment of Severe Metabolic Acidosis With Moderate or Severe Acute Kidney Injury in ICU N/A
Completed NCT02303548 - Bicarbonate in Patients With Out-of-hospital Cardiac Arrest Phase 2
Recruiting NCT01860001 - Incidence of Postoperative Ketosis and Metabolic Acidosis N/A
Completed NCT01452412 - Alkali Therapy in Chronic Kidney Disease Phase 2/Phase 3
Terminated NCT03710291 - Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis Phase 3
Completed NCT02476253 - Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill Phase 3
Completed NCT05940935 - The Relationship of Developing Metabolic Acidosis With Antiepleptic Drugs in Craniotomy Operations
Withdrawn NCT03846258 - High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy Phase 4
Completed NCT05970094 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Recruiting NCT05784389 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Terminated NCT04727528 - Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease Phase 3
Completed NCT02098356 - Comparison of High Versus Low Bicarbonate Hemodialysis N/A
Recruiting NCT03897101 - Inflammation and Metabolic Acidosis at Birth (AGAIN: AutophaGy AcIdosis Newborn)
Terminated NCT01894594 - Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease Phase 1
Completed NCT01075750 - Perioperative Fluid Management in Patients Receiving Cadaveric Renal Transplants N/A
Completed NCT01293266 - Effect of Propofol and Sevoflurane on Lactate During Anesthesia for Pediatric Heart Catheterisation N/A
Completed NCT01295190 - Substitution of Propofol by Sevoflurane During Pediatric Cardiopulmonary Bypass N/A